1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Asthma Drugs Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Asthma Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Asthma Drugs Market Regional Analysis
6.2 North America Asthma Drugs Market Revenue 2019-2028 (US$ Million)
6.3 North America Asthma Drugs Market Forecast Analysis
7. North America Asthma Drugs Market Analysis – by Medication
7.1 Quick Relief Medications
- 7.1.1 Overview
- 7.1.2 Quick Relief Medications: North America Asthma Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Long-Term Control Medications
- 7.2.1 Overview
- 7.2.2 Long-Term Control Medications: North America Asthma Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. North America Asthma Drugs Market Analysis – by Route of Administration
8.1 Inhaled
- 8.1.1 Overview
- 8.1.2 Inhaled: North America Asthma Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Prefilled Syringe/Vials
- 8.2.1 Overview
- 8.2.2 Prefilled Syringe/Vials: North America Asthma Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. North America Asthma Drugs Market Analysis – by Distribution Channel
9.1 Online Pharmacies
- 9.1.1 Overview
- 9.1.2 Online Pharmacies: North America Asthma Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Hospital Pharmacies
- 9.2.1 Overview
- 9.2.2 Hospital Pharmacies: North America Asthma Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Retail Pharmacies : North America Asthma Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
10. North America Asthma Drugs Market – North America Analysis
10.1 Overview
10.2 North America
- 10.2.1 North America Asthma Drugs Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 10.2.1.1 North America Asthma Drugs Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 US:
North America Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.1.1 US: North America Asthma Drugs Market Breakdown, by Medication
- 10.2.1.1.2 US: North America Asthma Drugs Market Breakdown, by Route of Administration
- 10.2.1.1.3 US: North America Asthma Drugs Market Breakdown, by Distribution Channel
- 10.2.1.2 Canada:
North America Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.2.1 Canada: North America Asthma Drugs Market Breakdown, by Medication
- 10.2.1.2.2 Canada: North America Asthma Drugs Market Breakdown, by Route of Administration
- 10.2.1.2.3 Canada: North America Asthma Drugs Market Breakdown, by Distribution Channel
- 10.2.1.3 Mexico :
North America Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.3.1 Mexico : North America Asthma Drugs Market Breakdown, by Medication
- 10.2.1.3.2 Mexico : North America Asthma Drugs Market Breakdown, by Route of Administration
- 10.2.1.3.3 Mexico : North America Asthma Drugs Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 AstraZeneca
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Boehringer Ingelheim International GmbH
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 GlaxoSmithKline plc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Merck & Co., Inc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Koninklijke Philips N.V.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Sanofi
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Pfizer Inc. (Arena Pharmaceutical GmbH)
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Novartis AG
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Abbott
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations